Abstract
Purpose: Clinical guidelines specify who should receive high-intensity statins; however, it is unclear how high-intensity statins are used in Australia. Our objective was to determine the demographic, clinical, and lifestyle factors associated with high-intensity statin therapy in Australia. Methods: Data from the Australian Diabetes, Obesity and Lifestyle study collected in 2011–2012 were analyzed. High-, moderate-, and low-intensity statins were defined as use of statins at doses demonstrated to reduce low-density lipoprotein cholesterol levels by > 50, 30–50, and < 30%, respectively. Logistic regression was used to estimate adjusted odd ratios (ORs) and 95% confidence intervals (CIs) for factors associated with high- versus low-to-moderate-intensity statin therapy. Results: Overall, 1108 (24%) study participants used a statin. Data on statin intensity were available for 1072 participants. The proportions of high-, moderate-, and low-intensity statin therapy were 32 (n = 341), 65 (n = 696), and 3% (n = 35), respectively. Overall, 51% of people with prior cardiovascular disease (CVD) used a high-intensity statin. In addition to prior CVD (OR = 3.34, 95% CI = 1.95–5.73), no (OR = 1.84, 95%CI 1.02–3.31) or insufficient physical activity (OR = 1.51, 95% CI = 1.01–2.25), obesity (OR = 1.87, 95% CI = 1.13–3.10), and consuming > 2 alcoholic drinks daily (OR = 1.66, 95% CI = 1.08–2.55) were associated with high versus low-to-moderate-intensity statin therapy. Conversely, age 65–74 vs. < 65 years was inversely associated with high-intensity statin therapy (OR = 0.62, 95% CI = 0.41–0.94). Conclusions: Prior CVD was the strongest factor associated with high-intensity statin therapy. Although the prevalence of CVD increases with age, older people were less likely to be treated with high-intensity statins.
| Original language | English |
|---|---|
| Pages (from-to) | 1493-1501 |
| Number of pages | 9 |
| Journal | European Journal of Clinical Pharmacology |
| Volume | 74 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 1 Nov 2018 |
Keywords
- Australia
- Cardiovascular disease
- Cholesterol
- Epidemiology
- HMG-CoA reductase inhibitors
Cite this
}
Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia : the AusDiab study. / Ho, Karen; Jamsen, Kris M.; Bell, J. Simon; Korhonen, Maarit Jaana; Mc Namara, Kevin P.; Magliano, Dianna J.; Liew, Danny; Ryan-Atwood, Taliesin E.; Shaw, Jonathan E.; Luc, Susan; Ilomäki, Jenni.
In: European Journal of Clinical Pharmacology, Vol. 74, No. 11, 01.11.2018, p. 1493-1501.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia
T2 - the AusDiab study
AU - Ho, Karen
AU - Jamsen, Kris M.
AU - Bell, J. Simon
AU - Korhonen, Maarit Jaana
AU - Mc Namara, Kevin P.
AU - Magliano, Dianna J.
AU - Liew, Danny
AU - Ryan-Atwood, Taliesin E.
AU - Shaw, Jonathan E.
AU - Luc, Susan
AU - Ilomäki, Jenni
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Purpose: Clinical guidelines specify who should receive high-intensity statins; however, it is unclear how high-intensity statins are used in Australia. Our objective was to determine the demographic, clinical, and lifestyle factors associated with high-intensity statin therapy in Australia. Methods: Data from the Australian Diabetes, Obesity and Lifestyle study collected in 2011–2012 were analyzed. High-, moderate-, and low-intensity statins were defined as use of statins at doses demonstrated to reduce low-density lipoprotein cholesterol levels by > 50, 30–50, and < 30%, respectively. Logistic regression was used to estimate adjusted odd ratios (ORs) and 95% confidence intervals (CIs) for factors associated with high- versus low-to-moderate-intensity statin therapy. Results: Overall, 1108 (24%) study participants used a statin. Data on statin intensity were available for 1072 participants. The proportions of high-, moderate-, and low-intensity statin therapy were 32 (n = 341), 65 (n = 696), and 3% (n = 35), respectively. Overall, 51% of people with prior cardiovascular disease (CVD) used a high-intensity statin. In addition to prior CVD (OR = 3.34, 95% CI = 1.95–5.73), no (OR = 1.84, 95%CI 1.02–3.31) or insufficient physical activity (OR = 1.51, 95% CI = 1.01–2.25), obesity (OR = 1.87, 95% CI = 1.13–3.10), and consuming > 2 alcoholic drinks daily (OR = 1.66, 95% CI = 1.08–2.55) were associated with high versus low-to-moderate-intensity statin therapy. Conversely, age 65–74 vs. < 65 years was inversely associated with high-intensity statin therapy (OR = 0.62, 95% CI = 0.41–0.94). Conclusions: Prior CVD was the strongest factor associated with high-intensity statin therapy. Although the prevalence of CVD increases with age, older people were less likely to be treated with high-intensity statins.
AB - Purpose: Clinical guidelines specify who should receive high-intensity statins; however, it is unclear how high-intensity statins are used in Australia. Our objective was to determine the demographic, clinical, and lifestyle factors associated with high-intensity statin therapy in Australia. Methods: Data from the Australian Diabetes, Obesity and Lifestyle study collected in 2011–2012 were analyzed. High-, moderate-, and low-intensity statins were defined as use of statins at doses demonstrated to reduce low-density lipoprotein cholesterol levels by > 50, 30–50, and < 30%, respectively. Logistic regression was used to estimate adjusted odd ratios (ORs) and 95% confidence intervals (CIs) for factors associated with high- versus low-to-moderate-intensity statin therapy. Results: Overall, 1108 (24%) study participants used a statin. Data on statin intensity were available for 1072 participants. The proportions of high-, moderate-, and low-intensity statin therapy were 32 (n = 341), 65 (n = 696), and 3% (n = 35), respectively. Overall, 51% of people with prior cardiovascular disease (CVD) used a high-intensity statin. In addition to prior CVD (OR = 3.34, 95% CI = 1.95–5.73), no (OR = 1.84, 95%CI 1.02–3.31) or insufficient physical activity (OR = 1.51, 95% CI = 1.01–2.25), obesity (OR = 1.87, 95% CI = 1.13–3.10), and consuming > 2 alcoholic drinks daily (OR = 1.66, 95% CI = 1.08–2.55) were associated with high versus low-to-moderate-intensity statin therapy. Conversely, age 65–74 vs. < 65 years was inversely associated with high-intensity statin therapy (OR = 0.62, 95% CI = 0.41–0.94). Conclusions: Prior CVD was the strongest factor associated with high-intensity statin therapy. Although the prevalence of CVD increases with age, older people were less likely to be treated with high-intensity statins.
KW - Australia
KW - Cardiovascular disease
KW - Cholesterol
KW - Epidemiology
KW - HMG-CoA reductase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85050292180&partnerID=8YFLogxK
U2 - 10.1007/s00228-018-2518-1
DO - 10.1007/s00228-018-2518-1
M3 - Article
VL - 74
SP - 1493
EP - 1501
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
SN - 0031-6970
IS - 11
ER -